The FDA announced it has approved elexacaftor/ivacaftor/tezacaftor, the first triple combination therapy for patients with the most common cystic fibrosis mutation.

The agency approved the therapy (Trikafta, Vertex Pharmaceuticals) for patients aged 12 years and older with cystic fibrosis who have one or more F508del mutations in the CFTR gene, according to a press release.